Jingjing Fu

68 Changle Road
Nanjing, 210006, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Dynamic phenotyping of radioiodine-refractory differentiated thyroid cancer: thyroglobulin trajectories, dual-modal imaging, and genotype-defined treatment resistance.

Dynamic phenotyping of radioiodine-refractory differentiated thyroid cancer: thyroglobulin trajectories, dual-modal imaging, and genotype-defined treatment resistance.

Journal: Frontiers in endocrinology
Published: May 26, 2026

Non-invasive detection of metastatic papillary thyroid carcinoma after radical surgery using salivary metabolomic biomarkers.

Non-invasive detection of metastatic papillary thyroid carcinoma after radical surgery using salivary metabolomic biomarkers.

Journal: Archives of endocrinology and metabolism
Published: February 26, 2026

Cross-Linking Profiling of Molecular Glue Degrader-Induced E3 Ligase Interactome to Expand Target Space.

Cross-Linking Profiling of Molecular Glue Degrader-Induced E3 Ligase Interactome to Expand Target Space.

Journal: Angewandte Chemie (International ed. in English)
Published: March 03, 2025

Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide, carnitine, choline and betaine.

Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide, carnitine, choline and betaine.

Journal: Journal of cancer research and clinical oncology
Published: January 12, 2024

Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.

Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.

Journal: Journal of the Endocrine Society
Published: December 07, 2023

Deep learning based on 68Ga-PSMA-11 PET/CT for predicting pathological upgrading in patients with prostate cancer.

Deep learning based on 68Ga-PSMA-11 PET/CT for predicting pathological upgrading in patients with prostate cancer.

Journal: Frontiers in oncology
Published: August 06, 2023

177 Lu-DOTATATE Therapy: Effects of Water Intake and Drinking Duration on Patient Peripheral Dose Equivalent Rates.

177 Lu-DOTATATE Therapy: Effects of Water Intake and Drinking Duration on Patient Peripheral Dose Equivalent Rates.

Journal: Health physics
Published: May 17, 2023

68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.

68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 29, 2021

Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.

Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.

Journal: Pancreas
Published: August 04, 2021

Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification.

Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification.

Journal: Journal of personalized medicine
Published: July 05, 2021

Combined use of 177 Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study.

Combined use of 177 Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study.

Journal: Journal of neuroendocrinology
Published: June 28, 2021

Anchoring Al- and/or Mg-oxides to magnetic biochars for Co-uptake of arsenate and fluoride from water.

Anchoring Al- and/or Mg-oxides to magnetic biochars for Co-uptake of arsenate and fluoride from water.

Journal: Journal of environmental management
Published: March 09, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026